Skip to content

Comparison of topical recombinant human epidermal growth factor versus aloe vera gel in combination with ablative 10,600-nm carbon dioxide fractional laser for the treatment of striae alba: A randomized, double-blind trial

Comparison of topical recombinant human epidermal growth factor versus aloe vera gel in combination with ablative 10,600-nm carbon dioxide fractional laser for the treatment of striae alba: A randomized, double-blind trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180610001
Enrollment
Unknown
Registered
2018-06-10
Start date
2017-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Striae alba striae alba&#44

Interventions

Each patient’s striae was divided into left and right side. Subjects have been treated with fractional CO2 laser on both sides for three treatments at four weeks interval. Immediately after the lase
each side of striae was randomly assigned to apply rh&#45
EGF or aloe vera gel and the subjects are required to apply the medication twice daily until 1 month after last laser treatment session.,Each patient’s striae was divided into left and right side. S
EGF or aloe vera gel and the subjects are required to apply the medication twice daily until 1 month after last laser treatment session.
Experimental Drug,Active Comparator Drug
rh&#45
EGF,Aloe vera gel

Sponsors

Thammasat University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: subjects aged 20-60, in good health, with striae alba on both sides of abdomen, thigh or buttock, able to remain 5kg of their starting weight during the study and avoid any non-study treatment of striae during the whole study period

Exclusion criteria

Exclusion criteria: history of keloids or hypertrophic scar, skin infection or other active skin disease on the study areas, use of immunosuppressive drug or systemic retinoid within past 2 months, any treatment including laser for striae within 1 year prior to study initiation, allergy to local anesthesia (e.g. lidocaine or prilocaine).

Design outcomes

Primary

MeasureTime frame
Texture of striae, Average malanin and melanin variation 9 months Anthera 3D Image

Secondary

MeasureTime frame
Side effectes such as erythema, scab and postinflammatory hyperpigmentation 9 months Investigator assessment

Contacts

Public ContactArisa Kaewkes

Thammasat University

searisa@yahoo.com+66895710956

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026